J Pathol Transl Med.  2017 May;51(3):205-223. 10.4132/jptm.2017.03.08.

Molecular Testing of Brain Tumor

• Park SH
• Won J
• Kim SI
• Lee Y
• Park CK
• Kim SK
• Choi SH

• KMID: 2392590
• DOI: http://doi.org/10.4132/jptm.2017.03.08

Abstract

The World Health Organization (WHO) classification of central nervous system (CNS) tumors was revised in 2016 with a basis on the integrated diagnosis of molecular genetics. We herein provide the guidelines for using molecular genetic tests in routine pathological practice for an accurate diagnosis and appropriate management. While astrocytomas and IDH-mutant (secondary) glioblastomas are characterized by the mutational status of IDH, TP53, and ATRX, oligodendrogliomas have a 1p/19q codeletion and mutations in IDH, CIC, FUBP1, and the promoter region of telomerase reverse transcriptase (TERTp). IDH-wildtype (primary) glioblastomas typically lack mutations in IDH, but are characterized by copy number variations of EGFR, PTEN, CDKN2A/B, PDGFRA, and NF1 as well as mutations of TERTp. High-grade pediatric gliomas differ from those of adult gliomas, consisting of mutations in H3F3A, ATRX, and DAXX, but not in IDH genes. In contrast, well-circumscribed low-grade neuroepithelial tumors in children, such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and ganglioglioma, often have mutations or activating rearrangements in the BRAF, FGFR1, and MYB genes. Other CNS tumors, such as ependymomas, neuronal and glioneuronal tumors, embryonal tumors, meningothelial, and other mesenchymal tumors have important genetic alterations, many of which are diagnostic, prognostic, and predictive markers and therapeutic targets. Therefore, the neuropathological evaluation of brain tumors is increasingly dependent on molecular genetic tests for proper classification, prediction of biological behavior and patient management. Identifying these gene abnormalities requires cost-effective and high-throughput testing, such as next-generation sequencing. Overall, this paper reviews the global guidelines and diagnostic algorithms for molecular genetic testing of brain tumors.

Keyword

Brain neoplasms; Molecular biology; Next generation sequencing; Pathological diagnosis

MeSH Terms

Adult
Astrocytoma
Brain Neoplasms*
Brain*
Central Nervous System
Child
Classification
Diagnosis
Ependymoma
Ganglioglioma
Genes, myb
Glioblastoma
Glioma
Humans
Molecular Biology
Neoplasms, Neuroepithelial
Neurons
Oligodendroglioma
Promoter Regions, Genetic
Telomerase
World Health Organization
Telomerase

Figure

• 

  Fig. 1. Schematic view of the classification of adult diffuse glioma according to the status of key genes.

• 

  Fig. 2. Schematic view of the classification of pediatric diffuse gliomas according to the status of key genes. LG, low grade; HG, high grade; NOS, not otherwise specified. aCharacteristic but not required for diagnosis.

• 

  Fig. 3. Schematic view, photographs, and reading criteria of the FISH probes for detecting 1p and 19q deletion. The FISH probes are long enough to find out the whole arm deletion. 1p/19q deleted cases show one orange signal and two green signals. The diagnostic cut-off of 1p and 10q deletion is written in the box. FISH, fluorescent in situ hybridization; LOH, loss of heterozygosity; CGH, comparative genomic hybridization; WES, whole exome sequencing.

Reference

1. Lee CH, Jung KW, Yoo H, Park S, Lee SH. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010; 48:145–52.

2. Jung KW, Ha J, Lee SH, Won YJ, Yoo H. An updated nationwide epidemiology of primary brain tumors in republic of Korea. Brain Tumor Res Treat. 2013; 1:16–23.

3. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015; 372:2481–98.

4. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155:462–77.

5. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9:157–73.

6. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321:1807–12.

7. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131:803–20.

8. Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015; 129:679–93.

9. Rajmohan KS, Sugur HS, Shwetha SD, et al. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the ‘integrated’ diagnosis approach. J Clin Pathol. 2016; 69:686–94.

10. Malzkorn B, Reifenberger G. Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. Curr Opin Oncol. 2016; 28:494–501.

11. Clark K, Voronovich Z, Horbinski C. How molecular testing can help (and hurt) in the workup of gliomas. Am J Clin Pathol. 2013; 139:275–88.

12. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015; 129:133–46.

13. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129:829–48.

14. Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev. 2017; 40:1–14.

15. Chan AK, Pang JC, Chung NY, et al. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol. 2014; 27:332–42.

16. Kreth S, Thon N, Kreth FW. Epigenetics in human gliomas. Cancer Lett. 2014; 342:185–92.

17. Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2015; 163:1–14.

18. Reis GF, Pekmezci M, Hansen HM, et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol. 2015; 74:442–52.

19. Simeonova I, Huillard E. In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cell Mol Life Sci. 2014; 71:4007–26.

20. Cachia D, Kamiya-Matsuoka C, Mandel JJ, et al. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015; 125:401–10.

21. Louis DN, Perry A, Burger P, et al. International Society of Neuropathology: Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014; 24:429–35.

22. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482:226–31.

23. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012; 124:439–47.

24. Solomon DA, Wood MD, Tihan T, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016; 26:569–80.

25. Zhang R, Han J, Daniels D, Huang H, Zhang Z. Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR. J Neurooncol. 2016; 126:27–36.

26. Nambirajan A, Malgulwar PB, Sharma MC, et al. C11orf95-RELA fusion present in a primary intracranial extra-axial ependymoma: report of a case with literature review. Neuropathology. 2016; 36:490–5.

27. Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro Oncol. 2016; 18:902–13.

28. Figarella-Branger D, Lechapt-Zalcman E, Tabouret E, et al. Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro Oncol. 2016; 18:919–27.

29. Nobusawa S, Hirato J, Sugai T, et al. Atypical teratoid/rhabdoid tumor (AT/RT) arising from ependymoma: a type of AT/RT secondarily developing from other primary central nervous system tumors. J Neuropathol Exp Neurol. 2016; 75:167–74.

30. Olar A, Sulman EP. Molecular markers in low-grade glioma-toward tumor reclassification. Semin Radiat Oncol. 2015; 25:155–63.

31. Capper D, Reifenberger G. Classification of gliomas: current progress and perspectives. Nervenarzt. 2015; 86:672–83.

32. Cachia D, Wani K, Penas-Prado M, et al. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. Brain Tumor Pathol. 2015; 32:105–11.

33. Nobusawa S, Hirato J, Yokoo H. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review. Brain Tumor Pathol. 2014; 31:229–33.

34. Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature. 2014; 506:451–5.

35. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121:397–405.

36. Tanboon J, Williams EA, Louis DN. The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol. 2016; 75:4–18.

37. Thomas L, Di Stefano AL, Ducray F. Predictive biomarkers in adult gliomas: the present and the future. Curr Opin Oncol. 2013; 25:689–94.

38. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013; 45:602–12.

39. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009; 118:401–5.

40. Tian Y, Rich BE, Vena N, et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn. 2011; 13:669–77.

41. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011; 121:763–74.

42. Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129:775–88.

43. Roth JJ, Fierst TM, Waanders AJ, Yimei L, Biegel JA, Santi M. Whole chromosome 7 gain predicts higher risk of recurrence in pediatric pilocytic astrocytomas independently from KIAA1549-BRAF fusion status. J Neuropathol Exp Neurol. 2016; 75:306–15.

44. Sredni ST, Tomita T. Rhabdoid tumor predisposition syndrome. Pediatr Dev Pathol. 2015; 18:49–58.

45. Hasselblatt M, Gesk S, Oyen F, et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol. 2011; 35:933–5.

46. Fruhwald MC, Biegel JA, Bourdeaut F, Roberts CW, Chi SN. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol. 2016; 18:764–78.

47. Diamandis P, Ferrer-Luna R, Huang RY, et al. Case report: next generation sequencing identifies a NAB2-STAT6 fusion in glioblastoma. Diagn Pathol. 2016; 11:13.

48. Han N, Kim H, Min SK, et al. Meningeal solitary fibrous tumors with delayed extracranial metastasis. J Pathol Transl Med. 2016; 50:113–21.

49. Maekawa A, Kohashi K, Yamada Y, et al. A case of intracranial solitary fibrous tumor/hemangiopericytoma with dedifferentiated component. Neuropathology. 2015; 35:260–5.

50. Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013; 45:285–9.

51. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013; 339:1077–80.

52. Reuss DE, Piro RM, Jones DT, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol. 2013; 125:351–8.

53. Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. Brain Tumor Pathol. 2016; 33:237–47.

54. Mehes G, Irsai G, Bedekovics J, et al. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry. Am J Surg Pathol. 2014; 38:1644–8.

55. Rodriguez FJ, Vizcaino MA, Lin MT. Recent advances on the molecular pathology of glial neoplasms in children and adults. J Mol Diagn. 2016; 18:620–34.

56. Maire CL, Ligon KL. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol. 2014; 16 Suppl 8:viii1–6.

57. Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol. 2016; 134:97–120.

58. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68:8673–7.

59. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27:5881–6.

60. Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol. 2016; 18:388–400.

61. Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016; 131:821–31.

62. Roth JJ, Santi M, Pollock AN, et al. Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade gliomas. Brain Pathol. 2015; 25:182–92.

63. Zhang ZY, Chan AK, Ding XJ, et al. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Oncotarget. 2015; 6:24871–83.

64. Bandopadhayay P, Ramkissoon LA, Jain P, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016; 48:273–82.

65. Qaddoumi I, Orisme W, Wen J, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 2016; 131:833–45.

66. Behling F, Barrantes-Freer A, Skardelly M, et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. 2016; 11:55.

67. Appin CL, Brat DJ. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. Adv Anat Pathol. 2015; 22:50–8.

68. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010; 465:966.

69. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462:739–44.

70. Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012; 18:5562–71.

71. Dimitrov L, Hong CS, Yang C, Zhuang Z, Heiss JD. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci. 2015; 12:201–13.

72. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17:510–22.

73. Appin CL, Brat DJ. Biomarker-driven diagnosis of diffuse gliomas. Mol Aspects Med. 2015; 45:87–96.

74. Claus EB, Walsh KM, Wiencke JK, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015; 38:E6.

75. Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treat Res. 2015; 163:15–30.

76. Jha P, Pia Patric IR, Shukla S, et al. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Neuro Oncol. 2014; 16:1607–17.

77. Swartling FJ. Myc proteins in brain tumor development and maintenance. Ups J Med Sci. 2012; 117:122–31.

78. Northcott PA, Pfister SM, Jones DT. Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncol. 2015; 16:e293–302.

79. Blumenthal DT, Dvir A, Lossos A, et al. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J Neurooncol. 2016; 130:211–9.

80. Ambros PF, Ambros IM; SIOP Europe Neuroblastoma Pathology, Biology, and Bone Marrow Group. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol. 2001; 37:492–504.

81. Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016; 18:649–55.

82. Clynes D, Higgs DR, Gibbons RJ. The chromatin remodeller ATRX: a repeat offender in human disease. Trends Biochem Sci. 2013; 38:461–6.

83. Gibbons RJ, McDowell TL, Raman S, et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat Genet. 2000; 24:368–71.

84. Chan KM, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013; 27:985–90.

85. Chen P, Zhao J, Wang Y, et al. H3.3 actively marks enhancers and primes gene transcription via opening higher-ordered chromatin. Genes Dev. 2013; 27:2109–24.

86. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012; 3:709–22.

87. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011; 333:1453–5.

88. Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol. 2012; 123:853–60.

89. Jiménez G, Shvartsman SY, Paroush Z. The Capicua repressor: a general sensor of RTK signaling in development and disease. J Cell Sci. 2012; 125(Pt 6):1383–91.

90. Chittaranjan S, Chan S, Yang C, et al. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget. 2014; 5:7960–79.

91. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74:5463–7.

92. Switzeny OJ, Christmann M, Renovanz M, Giese A, Sommer C, Kaina B. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Clin Epigenetics. 2016; 8:49.

93. Tritz R, Habita C, Robbins JM, Gomez GG, Kruse CA. Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: review article. Gene Ther Mol Biol. 2005; 9A:89–106.

94. Venkatesan S, Lamfers ML, Dirven CM, Leenstra S. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. CNS Oncol. 2016; 5:77–90.

95. Nikiforova MN, Wald AI, Melan MA, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol. 2016; 18:379–87.

96. Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015; 33:1015–22.

97. Yang P, Cai J, Yan W, et al. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016; 18:1099–108.

98. Chan AK, Yao Y, Zhang Z, et al. Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget. 2015; 6:20885–901.

99. Arita H, Narita Y, Takami H, et al. TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol. 2013; 126:939–41.

100. Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013; 126:267–76.

101. Heidenreich B, Rachakonda PS, Hosen I, et al. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget. 2015; 6:10617–33.

102. Chen C, Han S, Meng L, Li Z, Zhang X, Wu A. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. PLoS One. 2014; 9:e100297.

103. Arita H, Yamasaki K, Matsushita Y, et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016; 4:79.

104. Morrissy AS, Garzia L, Shih DJ, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016; 529:351–7.

105. Masliah-Planchon J, Machet MC, Fréneaux P, et al. SMARCA4-mutated atypical teratoid/rhabdoid tumor with retained BRG1 expression. Pediatr Blood Cancer. 2016; 63:568–9.

106. Sandgren J, Holm S, Marino AM, et al. Whole exome- and mRNA sequencing of an AT/RT case reveals few somatic mutations and several deregulated signalling pathways in the context of SMARCB1 deficiency. Biomed Res Int. 2015; 2015:862039.

107. Rode A, Maass KK, Willmund KV, Lichter P, Ernst A. Chromothripsis in cancer cells: an update. Int J Cancer. 2016; 138:2322–33.

108. Gajjar A, Pfister SM, Taylor MD, Gilbertson RJ. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. 2014; 20:5630–40.

109. Das A, Tan WL, Teo J, Smith DR. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway. J Neurooncol. 2002; 60:117–25.

110. Zascavage RR, Shewale SJ, Planz JV. Deep-sequencing technologies and potential applications in forensic DNA testing. Forensic Sci Rev. 2013; 25:79–105.

111. Cykowski MD, Allen RA, Fung KM, Harmon MA, Dunn ST. Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions. Diagn Mol Pathol. 2012; 21:214–20.

112. Quillien V, Lavenu A, Ducray F, et al. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. Oncotarget. 2016; 7:61916–29.

113. Havik AB, Brandal P, Honne H, et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med. 2012; 10:36.

114. Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients: The INFORM pilot study. Eur J Cancer. 2016; 65:91–101.

115. Sahm F, Schrimpf D, Jones DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016; 131:903–10.

116. Zacher A, Kaulich K, Stepanow S, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 2017; 27:146–59.

117. Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 2016; 13:3–11.

118. Lapin V, Mighion LC, da Silva CP, Cuperus Y, Bean LJ, Hegde MR. Regulating whole exome sequencing as a diagnostic test. Hum Genet. 2016; 135:655–73.

119. Woehrer A, Sander P, Haberler C, et al. FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice: a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). Clin Neuropathol. 2011; 30:47–55.

120. Jha P, Sarkar C, Pathak P, et al. Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: limitations and advantages in application to patient management. Diagn Mol Pathol. 2011; 20:40–7.

121. Idbaih A, Ducray F, Dehais C, et al. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One. 2012; 7:e45950.

122. Wiestler B, Capper D, Hovestadt V, et al. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol. 2014; 16:1630–8.

123. Gao K, Li G, Qu Y, et al. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas. Oncotarget. 2016; 7:8712–25.

124. Gessi M, Gielen GH, Dreschmann V, Waha A, Pietsch T. High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord. Acta Neuropathol. 2015; 130:435–7.

125. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011; 121:381–96.

126. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012; 123:473–84.

127. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012; 123:465–72.

128. Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol. 2002; 161:1997–2001.

129. Jakobiec FA, Kool M, Stagner AM, et al. Intraocular medulloepitheliomas and embryonal tumors with multilayered rosettes of the brain: comparative roles of LIN28A and C19MC. Am J Ophthalmol. 2015; 159:1065–74.

130. Cahill DP, Louis DN, Cairncross JG. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol. 2015; 4:287–94.

131. Jue TR, McDonald KL. The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol. 2016; 127:427–34.